Terms: = Ovarian cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Diagnosis
12 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of American College of Radiology ovarian-Adnexal Reporting and Data System ultrasound to predict malignancy risk in adnexal lesions.
Li Y; Shao G; Wu M; Zhang F; Zhang Y; Shao C
J Obstet Gynaecol Res; 2024 Feb; 50(2):225-232. PubMed ID: 37990446
[TBL] [Abstract] [Full Text] [Related]
3. Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
Tran DT; Vo VK; Le MT; Chuang L; Nguyen VQH
Gynecol Oncol; 2021 Jul; 162(1):113-119. PubMed ID: 33994145
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
Hu J; Jiao X; Zhu L; Guo H; Wu Y
BMC Cancer; 2020 Sep; 20(1):938. PubMed ID: 32993522
[TBL] [Abstract] [Full Text] [Related]
5. [cancers in systemic sclerosis : risk factors, impact on survival and literature review].
Catano J; Guedon A; Riviere S; Carrat F; Mahevas T; Fain O; Mekinian A
Rev Med Interne; 2019 Oct; 40(10):637-644. PubMed ID: 31255252
[TBL] [Abstract] [Full Text] [Related]
6. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract] [Full Text] [Related]
7. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank ovarian cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract] [Full Text] [Related]
8. Treating gynecologic malignancies in elderly patients.
Perri T; Katz T; Korach J; Beiner ME; Jakobson-Setton A; Ben-Baruch G
Am J Clin Oncol; 2015 Jun; 38(3):278-82. PubMed ID: 23689643
[TBL] [Abstract] [Full Text] [Related]
9. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
[TBL] [Abstract] [Full Text] [Related]
10. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.
Brard L; Weitzen S; Strubel-Lagan SL; Swamy N; Gordinier ME; Moore RG; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):176-80. PubMed ID: 16564074
[TBL] [Abstract] [Full Text] [Related]
11. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.
Sun Z; Fu X; Zhang L; Yang X; Liu F; Hu G
Anticancer Res; 2004; 24(2C):1159-65. PubMed ID: 15154641
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of immunosuppressive acidic protein in human ovarian cancer.
Lin YH; Chow SN; Chen CK; Chen RJ; Huang SC; Huang GT
J Formos Med Assoc; 1994 Sep; 93(9):776-80. PubMed ID: 7735007
[TBL] [Abstract] [Full Text] [Related]
